GlassScriptPhysician profile
Nanda K Nair
NPI 1265737126
$1,983.24
in general payments reported to CMS, 2019-2025
28 companies · $425 in 2025
The $425 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $102 · 2021: $146 · 2022: $63.61 · 2023: $127 · 2024: $403 · 2025: $425.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $955.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $427.13 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $268.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $225.67 | 2019-2025 | Farxiga, Wainua |
| Pfizer INC. | $171.55 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $81.38 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.82 | 2023-2024 | Jardiance |
| Alnylam Pharmaceuticals INC. | $68.47 | 2024-2025 | Onpattro |
| Amarin Pharma, INC. | $56.87 | 2019-2021 | |
| Nuwellis, INC. | $55.19 | 2019 | |
| Boston Scientific Corporation | $49.89 | 2024-2025 | General - Therapies |
| Scpharmaceuticals INC. | $44.32 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $42.57 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $42.11 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $35.99 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.61 | 2019-2024 | Lifevest |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $31.74 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $27.82 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $27.55 | 2025 | Attruby |
| Biosense Webster, INC. | $25.73 | 2025 | Carto 3 |
| Cvrx, INC. | $24.81 | 2025 | Barostim Neo System |
| Sanofi-Aventis U.S. LLC | $24.49 | 2019 | |
| Silk Road Medical, INC. | $24.00 | 2020 | |
| Esperion Therapeutics, INC. | $20.90 | 2021 | |
| Philips North America LLC | $20.06 | 2023 | |
| Astellas Pharma US INC | $20.03 | 2021 | |
| Inspire Medical Systems, INC. | $19.61 | 2025 | Inspire |
| Arbor Pharmaceuticals, INC. | $16.96 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $15.15 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nanda Nair listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.